Resmed RMD has unveiled a comprehensive brand evolution to lead the global sleep and health technology revolution. The strategy unifies all Resmed brands under a single health technology brand, aiming ...

RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment results that correspond to twice (200%) the daily percentage change of Rocket Lab, a company at the forefront of satellite ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase, and achieved $126 million in GAAP net income. The company’s subscriber base reached 2.2 million ...

March 7 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab ... fintechs and direct-to-consumer brands among others, the company said in a statement on Wednesday. category Trump defends tariffs ...

Hims & Hers Health (NYSE ... However, the U.S. FDA has determined that all four brand-name drugs are no longer in shortage.

We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Shares of Hims & Hers Health (HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its GLP-1 weight-loss drug Wegovy by more than half. The move obliterates ...

Hims & Hers Health stock took a hit when the FDA said there's no longer a shortage of Novo Nordisk's weight loss drugs. Now, a Texas court has raised the specter of an FDA ruling that the shortage ...